因子Xa阻害薬治療を受けている患者における重篤な出血の特徴、医療介入および転帰を記述する研究

基本情報

NCT ID

NCT06147830

ステータス

完了

試験のフェーズ

-

試験タイプ

観察

目標被験者数

2,202

治験依頼者名

AstraZeneca

概要

REVERXaL study aims to increase the understanding of the patient characteristics, bleeding presentation, health care interventions provided, and the clinical as well as self-reported health outcomes of patients with major bleeding in the presence of Factor Xa inhibitor treatment. The generation of insight on treatment approaches and associated outcomes in hospitalized patients with Factor Xa inhibitor-related major bleeds may inform clinical guidelines, health system decision making and streamline treatment pathways in this population.

対象疾患

介入

依頼者（Sponsor）